Andrew Cleeland , BS

CEO
Twelve, Inc

,

Andrew is an executive with 26 years of experience in the medical device industry. He is currently the president and CEO of Twelve, Inc.; a venture-funded company developing a percutaneous mitral valve replacement system and the twelfth company spun out of the premier medical device incubator The Foundry. He is also Vice Chairman of The Foundry and Chairman of Sympara Medical, a venture-funded company developing a novel, wearable, non-invasive treatment for hypertension. Most recently he was the president and CEO of Ardian, the pioneer of renal denervation for hypertension, heart failure and other associated disorders. Medtronic acquired Ardian in 2011 in one of the largest venture-funded exits in med-tech history. His experience includes both private and public sector roles. He started with the Australian Government’s Therapeutic Goods Administration, progressed to large med-tech companies in Telectronics Pacing Systems and Baxter Healthcare, then to three Silicon Valley start-ups; Radiant Medical, Ardian (including a brief stint at Medtronic) and now Twelve, Inc. He sits on the board of directors and acts as an advisor to a number of lifescience companies. He holds a Bachelor of Applied Science (Biophysics) from the Swinburne Institute of Technology.